GO
Loading...

Ireland

More

  • FACTBOX-How Europe's "bad banks" have fared Monday, 2 Mar 2015 | 12:12 PM ET

    Belgium had two major banking failures, Fortis and Dexia. With the former, toxic assets were purchased for 11.7 billion euros by a separate vehicle Royal Park Investments, owned by Fortis, the Belgian state and BNP Paribas. Credit Suisse and Lone Star Funds bought RPI's assets for 6.7 billion euros in 2013. RPI is active now only in U.S. legal disputes.

  • DUBLIN/ MADRID, March 2- Europe's tough treatment of Greece's new government has eased some immediate anti-austerity pressure in Ireland and Spain, but it may take a lot more than that to put Dublin and Madrid's ruling parties' re-election prospects back on track. They both toed the line with Germany in demanding that Greece stick to its bailout commitments- a...

  • Endo reports 4Q loss Monday, 2 Mar 2015 | 7:21 AM ET

    DUBLIN 4, Ireland _ Endo International PLC on Monday reported a loss of $53.5 million in its fourth quarter. The Dublin 4, Ireland- based company said it had a loss of 35 cents per share. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.13 per share.

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • Horizon Pharma reports 4Q loss Friday, 27 Feb 2015 | 7:21 AM ET

    DUBLIN _ Horizon Pharma Inc. on Friday reported a loss of $31.6 million in its fourth quarter. The Dublin- based company said it had a loss of 27 cents per share. For the year, the company reported that its loss widened to $263.6 million, or $3.15 per share.

  • Global Indemnity posts 4Q profit Friday, 27 Feb 2015 | 5:13 AM ET

    DUBLIN _ Global Indemnity PLC on Thursday reported fourth-quarter profit of $11.1 million. The Dublin- based company said it had profit of 44 cents per share. Keywords: Global Indemnity, Earnings Report.

  • DUBLIN, Feb 26- Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between 275 million and 325 million euros in one of Europe's biggest biotechnology IPOs. Former Elan chief executive Kelly Martin and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for...

  • Feb 26- Google Inc has combined its two European regional divisions as it seeks to meet the challenges of tougher regulation across the continent, a source close to the company said on Thursday. In response, Google has argued that for Europe to remain competitive in global markets, it needs to form a single digital market instead of relying on national...

  • FDA approves new antibiotic combo from Actavis Wednesday, 25 Feb 2015 | 6:02 PM ET

    The drug from Actavis PLC contains two ingredients, cephalosporin and avibactam, designed to help fight antibiotic-resistant bacteria. The Food and Drug Administration approved Avycaz to treat certain abdominal infections, in combination with another drug, and for complicated urinary-tract infections, including kidney infections, for which there are...

  • LONDON, Feb 25- Ireland has no problem in principle with the idea of swapping Greece's official debt for growth-linked bonds but would have to see the details of any proposal, Finance Minister Michael Noonan said on Wednesday. Euro zone finance ministers agreed on Tuesday to a four-month extension of Greece's EU/IMF bailout programme, subject to its economic...

  • Jazz tops Street 4Q forecasts Tuesday, 24 Feb 2015 | 7:09 PM ET

    DUBLIN _ Jazz Pharmaceuticals PLC on Tuesday reported fourth-quarter net income of $81.6 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $2.34 per share. Analysts expected $321 million, according to Zacks.

  • Alkermes beats Street 4Q forecasts Tuesday, 24 Feb 2015 | 11:58 AM ET

    DUBLIN _ Alkermes PLC on Tuesday reported fourth-quarter earnings of $30.5 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 4 cents per share. Alkermes shares have increased 26 percent since the beginning of the year.

  • Feb 24- Facebook Inc said on Tuesday that its active advertisers rose to 2 million, a 33 percent increase from the 1.5 million it had in July 2014. Facebook does not break out the actual number of small business advertisers versus big brands, but they tend to spend on average $5 to $50 a day. Sandberg said that the fastest areas of growth of small business advertising...

  • HELSINKI— Apple is investing 1.7 billion euros in high-tech data centers in Denmark and Ireland that will be powered by renewable energy, in its largest such project in Europe to date, the company said Monday. The hubs, to begin operations in 2017, will power data for Apple Inc.' s online services, including iTunes Store, App Store, iMessage, Maps and Siri voice...

  • Feb 23- Apple Inc said it would spend 1.7 billion euros to build two data centres in Europe that would be entirely powered by renewable energy and create hundreds of jobs. The company said the centres, in Ireland and Denmark, will power Apple's online services, including the iTunes Store, App Store, iMessage, Maps and Siri for customers across Europe.

  • Germany's Wolfgang Schaeuble, the "immovable object" in the words of one economist, stopped Greece's charismatic new finance minister Yanis Varoufakis in his tracks, forcing Athens to extend a bailout program on Friday on terms its government was just elected to get out of. More than that, the confusion officials recounted from behind the scenes left mutual...

  • NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...

  • UPDATE 2-Actavis beats profit estimates, raises forecast Wednesday, 18 Feb 2015 | 9:11 AM ET

    Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  • Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...

  • Actavis reports 4Q loss Wednesday, 18 Feb 2015 | 6:54 AM ET

    DUBLIN _ Actavis PLC on Wednesday reported a loss of $732.9 million in its fourth quarter. Actavis expects full-year earnings in the range of $16.30 to $17.30 per share. Actavis shares have increased 11 percent since the beginning of the year, while the Standard& Poor's 500 index has increased 2 percent.